Your browser doesn't support javascript.
Effect and safety of Chinese herbal medicine granules in patients with severe coronavirus disease 2019 in Wuhan, China: a retrospective, single-center study with propensity score matching.
Wang, Yuanyuan; Liu, Yuntao; Lv, Qingquan; Zheng, Danwen; Zhou, Li; Ouyang, Wenwei; Ding, Banghan; Zou, Xu; Yan, Fang; Liu, Bo; Chen, Jun; Liu, Tianzhu; Fu, Chicheng; Fang, Qu; Wang, Yi; Li, Fang; Chen, Ailan; Lundborg, Cecilia Stålsby; Guo, Jianwen; Wen, Zehuai; Zhang, Zhongde.
  • Wang Y; Department of Emergency, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China; Department of Global Public Health, Karolinska Institute, Stockholm, Sweden.
  • Liu Y; Department of Emergency, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China; Guangdong Provincial Key Laboratory of Research on Emergency in TCM, Guangzhou, China.
  • Lv Q; Department of Medical Administration, Wuhan Hankou Hospital, Wuhan, China.
  • Zheng D; Department of Emergency, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Zhou L; Key Unit of Methodology in Clinical Research, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Ouyang W; Department of Global Public Health, Karolinska Institute, Stockholm, Sweden; Key Unit of Methodology in Clinical Research, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Ding B; Department of Emergency, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Zou X; Intensive Care Unit, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Yan F; Department of Internal Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Liu B; Department of Radiology, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Chen J; Department of Radiology, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Zhuhai, China.
  • Liu T; Department of Radiology, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Zhuhai, China.
  • Fu C; Shanghai Aitrox Technology Corporation Limited, Shanghai, China.
  • Fang Q; Shanghai Aitrox Technology Corporation Limited, Shanghai, China.
  • Wang Y; Shanghai Aitrox Technology Corporation Limited, Shanghai, China.
  • Li F; Department of Emergency, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Chen A; Department of Cardiology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Lundborg CS; Department of Global Public Health, Karolinska Institute, Stockholm, Sweden.
  • Guo J; Department of Neurology, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. Electronic address: jianwen_guo@qq.com.
  • Wen Z; Key Unit of Methodology in Clinical Research, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. Electronic address: wenzh@gzucm.edu.cn.
  • Zhang Z; Department of Emergency, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China; Guangdong Provincial Key Laboratory of Research on Emergency in TCM, Guangzhou, China; State Key Laboratory of Dampness Syndrome of Chinese Medicine, the Second Affiliated Hospital
Phytomedicine ; 85: 153404, 2021 May.
Article in English | MEDLINE | ID: covidwho-909314
ABSTRACT

BACKGROUND:

Chinese herbal medicine (CHM) has been used for severe illness caused by coronavirus disease 2019 (COVID-19), but its treatment effects and safety are unclear.

PURPOSE:

This study reviews the effect and safety of CHM granules in the treatment of patients with severe COVID-19.

METHODS:

We conducteda single-center, retrospective study on patients with severe COVID-19 in a designated hospital in Wuhan from January 15, 2020 to March 30, 2020. The propensity score matching (PSM) was used to assess the effect and safety of the treatment using CHM granules. The ratio of patients who received treatment with CHM granules combined with usual care and those who received usual care alone was 11. The primary outcome was the time to clinical improvement within 28 days, defined as the time taken for the patients' health to show improvement by decline of two categories (from the baseline) on a modified six-category ordinal scale, or to be dischargedfrom the hospital before Day 28.

RESULTS:

Using PSM, 43 patients (45% male) aged 65.6 (57-70) yearsfrom each group were exactly matched. No significant difference was observed in clinical improvement of patients treated with CHM granules compared with those who received usual (p = 0.851). However, the use of CHM granules reduced the 28-day mortality (p = 0.049) and shortened the duration of fever (4 days vs. 7 days, p = 0.002). The differences in the duration of cough and dyspnea and the difference in lung lesion ratio on computerized tomography scans were not significant.Commonly,patients in the CHM group had an increased D-dimer level (p = 0.036).

CONCLUSION:

Forpatients with severe COVID-19, CHM granules, combined with usual care, showed no improvement beyond usual care alone. However, the use of CHM granules reduced the 28-day mortality rate and the time to fever alleviation. Nevertheless, CHM granules may be associated with high risk of fibrinolysis.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Drugs, Chinese Herbal / COVID-19 Drug Treatment Type of study: Experimental Studies / Observational study / Prognostic study Topics: Traditional medicine Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: Phytomedicine Journal subject: Complementary Therapies Year: 2021 Document Type: Article Affiliation country: J.phymed.2020.153404

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Drugs, Chinese Herbal / COVID-19 Drug Treatment Type of study: Experimental Studies / Observational study / Prognostic study Topics: Traditional medicine Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: Phytomedicine Journal subject: Complementary Therapies Year: 2021 Document Type: Article Affiliation country: J.phymed.2020.153404